Who are Phase 2: Amisulpride's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ropinirole CR-RLS, Ropinirole (Requip), [11C]raclopride, Raclopride C11, aripiprazole long acting injectable formulation, IM aripiprazole once monthly.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/phase-2-amisulpride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Phase 2: Amisulpride — Competitive Intelligence Brief

Phase 2: Amisulpride (Phase 2: Amisulpride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic. Area: Psychiatry.

phase 3 Atypical antipsychotic Dopamine D2 receptor, Dopamine D3 receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Phase 2: Amisulpride (Phase 2: Amisulpride) — Shanghai Mental Health Center. Amisulpride is a selective dopamine D2 and D3 receptor antagonist that blocks dopamine signaling in the brain to reduce psychotic symptoms and improve mood.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Phase 2: Amisulpride TARGET	Phase 2: Amisulpride	Shanghai Mental Health Center	phase 3	Atypical antipsychotic	Dopamine D2 receptor, Dopamine D3 receptor
ropinirole CR-RLS	ropinirole CR-RLS	GlaxoSmithKline	marketed	Dopamine D2/D3 receptor agonist	Dopamine D2 receptor, Dopamine D3 receptor
Ropinirole (Requip)	Ropinirole (Requip)	St. Luke's-Roosevelt Hospital Center	marketed	Dopamine D2/D3 receptor agonist	Dopamine D2 receptor, Dopamine D3 receptor
[11C]raclopride	[11C]raclopride	New York State Psychiatric Institute	marketed	Dopamine D2/D3 receptor antagonist (PET imaging agent)	Dopamine D2 receptor, Dopamine D3 receptor
Raclopride C11	Raclopride C11	University of North Carolina, Chapel Hill	marketed	Dopamine D2/D3 receptor antagonist (PET imaging agent)	Dopamine D2 receptor, Dopamine D3 receptor
aripiprazole long acting injectable formulation	aripiprazole long acting injectable formulation	Vanguard Research Group	marketed	Atypical antipsychotic (dopamine partial agonist)	Dopamine D2 receptor, Dopamine D3 receptor
IM aripiprazole once monthly	IM aripiprazole once monthly	University of Utah	marketed	Atypical antipsychotic	Dopamine D2 receptor, Dopamine D3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic class)

Shanghai Mental Health Center · 10 drugs in this class
AstraZeneca · 6 drugs in this class
Otsuka Pharmaceutical Development & Commercialization, Inc. · 5 drugs in this class
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 4 drugs in this class
Eli Lilly and Company · 4 drugs in this class
Otsuka Pharmaceutical Co., Ltd. · 3 drugs in this class
Medical University of Vienna · 2 drugs in this class
Organon and Co · 2 drugs in this class
Chengdu Kanghong Pharmaceutical Group Co., Ltd. · 2 drugs in this class
H. Lundbeck A/S · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Phase 2: Amisulpride — Competitive Intelligence Brief. https://druglandscape.com/ci/phase-2-amisulpride. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab